chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Had vaccine two weeks ago broke out  with mild case of pox, approximately 40, generalized.    Se temperture
Patient presented on 04/24/2010 with symmetrical and bilateral limb weakness. Patient also presented with decreased deep tendon reflexes. LP was performed on patient on 4/25/2010.
Started feeling hot and flush pretty immediately felt dizzy very shortly felt throat closing, like I had a golf ball my throat and my heart started heart racing. Staff provided medical treatment  immediately put me on a pulse ox and my heart race was up, kept monitoring me. Pretty quickly I started feeling better in about 10 min. No tests were done or meds administered. After about 10 min all was better I just feel tired and a little bit dizzy. They monitored me about 30 min  - I received gatorade and was observed for about 30 min and they let me go since I just felt tired.
First 3 days: Fatigue, fever, loss of appetite ( lost 6 pound) headache, heart racing, shortness of breath, dizziness.  10 days to 14 days: Continued shortness of breath, dizziness (more frequent laying down) and increased blood pressure.
Information has been received from a physician concerning a 65 year old female who on 4/16/90 was vaccinated with the hep B vaccine. The physician reported that the pt subsequently developed common variable immune deficiency. Unspecified medical attention was sought. At the time of this report, the outcome was unknown. The physician felt that the common variable immune deficiency was not related to the hep B vaccine. Upon internal review, common variable immune deficiency was determined to be an other important medical event (OMIC). Additional info has been requested. Because the license for Heptavax-B was withdrawn, this report is being submitted under the PLA for Recombivax-HB.
Telephone call with 3/18/04. Mom first noticed 1 spot on forehead and 1 on the knee Tues evening 3-9-04- thought it was bug bites/ 3-10-04 (Wed) noticed 2 spots on left FA (one was big spot where vaccine was)/ 3-11-04 (Thurs) Approx 20 lesions scattered all over body and no temp. School nurse notified. Nurse reported to Health Bureau. Pt seen at Doctor's office 3-15-2004 told had mild case of varicella right thigh vaccine.
Information has been received from a registered nurse concerning a 47year old male construction worker with no past medical history and no allergies, who on 8/20/02 was vaccinated with a dose of pneumococcal vaccine 23 polyvalent (lot # 637263/1448K) that expired on 6/1/02. There was no concomitant vaccination. At the time of vaccination, the patient was experiencing arthralgia due to over use. Unspecified medical attention was sought, but there were no adverse events. On 10/1/02 the patient had a negative streptococcus pneumoniae Ag test and per the physician the patient needs pneumococcal vaccine 23 polyvalent. Additional information is not expected.
Pain started in one arm and then slowly radiated across chest to the other arm, back, and shoulder.
Information has been received from a nurse referring to multiple unknown patients of unknown age and gender. Concurrent condition and medical history of the patients were not reported. On unknown dates, the patients were vaccinated with doses of VAQTA (lot #L015460, expiration date: 20-JUL-2017 and lot# M009377, expiration date: 17-JUN-2017 (dose and route unspecified). These vaccines had been through a temperature excursion at 34 degree Fahrenheit for 10 minutes (incorrect storage of drug). Previous temperature excursion of the vaccines included 35 degree Fahrenheit for 10 minutes. No adverse effects were reported. Additional information has been requested.
24 hrs following vax became ill w/earaches, sore throat, bad cold, severe coughing; no fever; called MD; as of 10NOV92 pt still having same sx;
Fever up to 101, redness and swelling at the injection site and slight loss of appetite.
Chills; Back ache; Tired; This is a spontaneous report from a contactable consumer, the patient. A 49-year-old non-pregnant female patient received an unknown dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 30Aug2021 (at the age of 49-years-old) as a single dose for COVID-19 immunisation. Medical history included COVID-19 on an unknown date. Prior to the vaccination, the patient was diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications were not reported. On 01Sep2021, the patient experienced chills, back ache and tired. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events chills, back ache and tired were recovered on an unknown date in Sep2021.   The lot number for BNT162b2 was not provided and will be requested during follow up.
This spontaneous report as received from a medical assistant refers to a patient of unknown age and gender. There was no information about the patient's concurrent conditions, concomitant therapies or medical history provided. On 17-JUL-2017, the patient received expired dose of ROTATEQ oral liquid, lot # M004508, expiration date 29-JUN-2017 (dose and frequency were not reported) for prophylaxis. No adverse effect was reported. Additional information has been requested.
Had a weried sensation in her head during the injection. 10 min after receiving the COVID vaccine she reported not feeling well ranf had a burning sensation throughour her body.  Has burining sensation on face, rash on chest , face amd arms, started to sweat, hair and uniform became wet, she was them taken to the ED.  B/p 166/100 became elevated, pule rate over 100.  Was prescribed benadryl, epipen, prednisone. Next day felt better, had some itching  rach under her breast and have light headaches.  Taking prescribed medicine including Benadryl
REACTIVE ARTHRITIS (SEVERE PAIN); This spontaneous report received from a patient concerned a patient of unspecified age, sex, unknown race and ethnicity. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unknown and expiry: UNKNOWN) 1 total, dose, start therapy date were not reported for prophylactic vaccination. The batch number was not reported. Per procedure, no follow-up will be requested for this case. No concomitant medications were reported.  On an unspecified date in JUL-2021, the patient was diagnosed with reactive arthritis. The patient is still in severe pain after three weeks. Laboratory data included: Lab test (NR: not provided) diagnosed with Reactive Arthritis. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient had not recovered from reactive arthritis (severe pain) This report was serious (Other Medically Important Condition).; Sender's Comments: V0-20210822977-Covid-19 vaccine ad26.cov2.S-Reactive arthritis (severe pain).This event(s) is considered unassessable. The event(s) has a compatible/suggestive temporal relationship, is unlabeled, and has unknown scientific plausibility. There is no information on any other factors potentially associated with the event(s).
Information has been received from a physician concerning a 36 year old female with hypertension, fibromyalgia and questionable allergy to penicillin from childhood who on 1/20/2006 was vaccinated IM in the deltoid with the first 0.5ml dose of hepatitis B virus vaccine rHBsAg (yeast). Concomitant therapy included labetalol HCL and cyclobenzaprine HCL Flexeril. The physician reported that in the middle of the night on 1/21/2006, the patient awoke with difficulty swallowing. The patient went to the ER, was diagnosed with uvula swelling and was treated with prednisone and amoxicillin. The patient was subsequently discharged from the ER after receiving treatment. On 1/23/2006, the patients uvula swelling resolved. The reporting physician considered the uvula swelling to be immediately life threatening and an other important medical event (OMIC). Additional information has been requested.
Numb throat; This is a spontaneous report from a contactable Consumer. This 65-year-old female Consumer (patient herself) reported in response to consumer letter sent via follow-up letter which included. A 65-years-old female patient received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Solution for injection, Lot Number: EN6198) via an unspecified route of administration, administered in arm right on an unspecified date at 09:30 (at the age of 65-years-old) as dose 2, single for COVID-19 immunization. Medical history included systemic lupus erythematosus, chronic kidney disease and hypertension from an unknown date and unknown if ongoing. Previously patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Solution for injection, Lot Number: EN5818) via an unspecified route of administration, administered in arm right on an unspecified date 09:30 as dose 1, single for COVID-19 immunization. Concomitant medications included amlodipine taken for an unspecified indication from 2020 and ongoing. From 2000 patient received hctz (HCTZ) and losartan taken for an unspecified indication and ongoing. From 2009 she received acetylsalicylic acid (ASPIRIN (E.C.)) taken for an unspecified indication and ongoing, and atorvastatin calcium (LIPITOR ORIFARM) taken for an unspecified indication and ongoing again from 2020. On an unspecified date at 09:30 the patient experienced numb throat and on the same day at 09:45 she experienced nausea, headache and felt fever. On an unspecified date the patient underwent lab tests and procedures which included blood test except HBP as unknown results. Admission to hospital Involved reported as no. Patient was experienced fine at the time of this report. No treatment Received. The outcome of the event numb throat was recovered.  No follow up attempts are possible. No further information is expected.
Information has been received on 10-JAN-2019 regarding a case in litigation from a lawyer concerning a female patient of unknown age. There was no information provided regarding the patient's concurrent conditions, medical history or concomitant medications. In or around December 2014, the patient was inoculated with the ZOSTAVAX (lot number, expiration, dose and route unknown) for routine health maintenance and for its intended purpose: the prevention of shingles. Shortly after receiving the ZOSTAVAX, the patient suffered shingles. As a direct and proximate result of ZOSTAVAX the patient's symptoms have resulted in physical limitations not present prior to using ZOSTAVAX. The patient also experiences mental and emotional distress due to resulting physical limitations and seriousness of the patient's condition. As a result of ZOSTAVAX, the patient sustained severe and permanent personal injuries. Further, as a tragic consequence of ZOSTAVAX, the patient suffered serious, progressive, permanent and incurable injuries, as well as conscious pain and suffering, mental anguish, emotional distress, loss of enjoyment of life, physical impairment and injury. The patient has suffered and incurred damages, including medical expenses, loss of accumulations and other economic and non-economic damages. As a direct and proximate consequence of ZOSTAVAX, the patient sustained serious personal injuries and related losses including but not limited to the patient required and will continue to require healthcare and services; the patient incurred and will continue to incur medical and related expenses; and the patient suffered and will continue to suffer mental anguish, physical pain and suffering, diminished capacity for the enjoyment of life, a diminished quality of life and other losses and damages. The patient has paid and has become liable to pay for medical aid, treatment, monitoring, medications and other expenditures and will necessarily incur further expenses of a similar nature in the future as a proximate result of ZOSTAVAX. The outcome of the events is not recovered. The causality of the events is related. Shingles was considered to be disabling. Additional information has been requested.
This spontaneous report was received from the registered nurse regarding a 11 years old patient of unknown gender. The patient's medical history, concurrent conditions, drug allergies/reactions and concomitant medications were not provided. On 23-OCT-2018, the patient was vaccinated with improperly stored VARIVAX (product storage error) lot # N031001 and expiration date 03-NOV-2019 (doses, frequencies, routes were not provided) for prophylaxis which were reconstituted with a properly stored sterile diluent (unknown manufacturer) lot # M037021 with expiration date 04-MAY-2019. The vaccine was stored at a temperature of -9 degree Celsius to 8 degree Celsius, time frame of 2 hours and 15 minutes. The vaccine was also stored out of range at -6 degree Celsius for an approximate time of 15 minutes. There was no previous temperature excursion. Digital Data logger was involved. The date of VARIVAX storage error was 22-JUL-2018. No adverse events were reported. The outcome of the event product storage error and no adverse event were unknown. This is one of the several report received from same reporter. Sender's Comments: US-009507513-1807USA011693.
Dizziness; weakness; Sore Left Shoulder and left side of the Neck; Nausea; Dry Back of Throat; Stomach Cramps; Diarrhea; Body Aches; Wavering pain comes and goes in the same places; This spontaneous case was reported by a consumer and describes the occurrence of DRY THROAT (Dry Back of Throat), ABDOMINAL PAIN UPPER (Stomach Cramps), DIARRHOEA (Diarrhea), PAIN (Body Aches) and PAIN (Wavering pain comes and goes in the same places) in a 60-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 012A21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included Nasal abscess. Concurrent medical conditions included Anxiety disorder. Concomitant products included CLONAZEPAM for Anxiety disorder.    On 28-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 28-Feb-2021, the patient experienced DRY THROAT (Dry Back of Throat), ABDOMINAL PAIN UPPER (Stomach Cramps), DIARRHOEA (Diarrhea), PAIN (Body Aches), PAIN (Wavering pain comes and goes in the same places), ARTHRALGIA (Sore Left Shoulder and left side of the Neck) and NAUSEA (Nausea). On an unknown date, the patient experienced DIZZINESS (Dizziness) and ASTHENIA (weakness). At the time of the report, DRY THROAT (Dry Back of Throat), ABDOMINAL PAIN UPPER (Stomach Cramps), DIARRHOEA (Diarrhea), PAIN (Body Aches), PAIN (Wavering pain comes and goes in the same places), DIZZINESS (Dizziness), ASTHENIA (weakness), ARTHRALGIA (Sore Left Shoulder and left side of the Neck) and NAUSEA (Nausea) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No treatment medication was provided.   Most recent FOLLOW-UP information incorporated above includes: On 27-Apr-2021: New events Weakness and Dizziness were added. On 16-Jul-2021: Non significant follow up received on 16-Jul-2021 included last name of primary reporter (patient).
Approximately 10 minutes after receiving the dose I lost all of  my vision in a pixelated-like blackout. Vomited multiple times after my vision slowly came back. The teller said I was green and pale.
chest congestion; consisting of headache; sore throat; fever; shortness of breath; diarrhea; facial pain; burning sinuses; now she was weak; This is a spontaneous report based on the information received by Pfizer from Allergan (Manufacturer Report Number: AGN255108). A contactable consumer reported that a 6-decade-old female patient (not pregnant)received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration on 20Jan2021 at single dose for COVID-19 immunization. Medical history and concomitant medications were not reported. The patient previously took Botox for 8-10 years for Cervical Dystonia and in the beginning she had torticollis. The Botox straightened out her torticollis, which caused unspecified allergies for which she took Allegra-D. Her last Botox treatment was in Oct2020. She was past due for Botox due to having to take the Covid-19 vaccine. The patient got a Covid-19 vaccine on 20Jan2021. On 21Jan2021 she began having a "reaction" to the vaccine, consisting of headache, sore throat, fever, chest congestion, shortness of breath, diarrhea, facial pain, and burning sinuses. It took 24 hours after the vaccine to show symptoms, events began 21Jan2021. The symptoms were ongoing and now she was weak, and was unsure how long she will be at work today. There had been no treatment for the symptoms. The outcome of the events were not resolved.  Information on lot number/batch number has been requested.
Tingling in the face that led to numbness and slight swelling on the left side of my face. Started 20 minutes after injection.
Covid-19; Coughing; Chills; Body aches; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (Covid-19), COUGH (Coughing), CHILLS (Chills) and MYALGIA (Body aches) in a 25-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 026L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 16-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 16-Jan-2021, the patient experienced COUGH (Coughing), CHILLS (Chills) and MYALGIA (Body aches). On 28-Mar-2021, the patient experienced COVID-19 (Covid-19). The patient was treated with GUAIFENESIN (MUCINEX) at an unspecified dose and frequency. At the time of the report, COVID-19 (Covid-19), COUGH (Coughing), CHILLS (Chills) and MYALGIA (Body aches) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No Concomitant medications were provided
This case was reported by a physician and described the occurrence of severe knee, shoulders and hands joint pain in a 46-year-old female subject who was vaccinated with FLULAVAL (GlaxoSmithKline). Concurrent medical conditions included allergies, colon cancer with no treatment in four months and high blood pressure. Concurrent medications included BYSTOLIC, CLARITIN, Ibuprofen and PERCOCET. The subject had not experienced any adverse events following previous vaccinations. On 11 October 2010 at 15:00 the subject received unspecified dose of FLULAVAL (unknown, right arm). On 19 October 2010, 8 days after vaccination with FLULAVAL, the subject experienced severe knee, shoulders and hands joint pain and walking difficulty. On 23 October 2010, 12 days after vaccination with FLULAVAL, she experienced low grade fever. The subject required medical attention at a doctor's office. The physician considered the events were disabling and clinically significant (or requiring intervention). Relevant test results included high sedimentation rate and high rheumatoid factor. She was evaluated by X-ray and there was no sign of rheumatoid arthritis. At the time of reporting, the severe knee, shoulders, and hands joint pain were worse and the low grade fever was unresolved. The physician considered the events were possibly related to vaccination with FLULAVAL.
Pharmacist reported that the patient has been diagnosed with HPV infection since receiving 2 of the 3 GARDASIL 9 vaccines 2 years ago; The patient already had 2 of 3 doses of GARDASIL 9 about 2 years ago but did not complete the series not receiving the third and final dose. Pharmacist was seeking advice on restarting vaccination series versus just given the third missed dose; This spontaneous report was received from a pharmacist referring to an adult female patient of unspecified age. The patient's concurrent conditions, historical conditions, concomitant therapies, and allergies were not reported.  In approximately 2021 (reported as about 2 years ago), when the patient was about 23-year-old, she received two (2) of the three (3) dose regimen prescribed by a physician of HPV rL1 6 11 16 18 31 33 45 52 58 VLP vaccine (yeast) (GARDASIL9) injection, administered intramuscularly (strengths, dosages, anatomical sites of application, lot numbers and expiration dates were not reported) for an indication stated as human papillomavirus (HPV) (prophylaxis).   On an unspecified date, since receiving 2 of the 3 HPV rL1 6 11 16 18 31 33 45 52 58 VLP vaccine (yeast) (GARDASIL9), the patient was diagnosed with HPV infection (papilloma viral infection). Additionally, it was reported that the patient did not complete the series and not received the third and final dose (inappropriate schedule of product administration). Therefore, the pharmacist was seeking for advice on restarting vaccination series versus just giving the third missed dose. It was unknown by the reporter if lab diagnostics or studies were performed, and if any treatment was given for the event. At the reporting time, the outcome of papilloma viral infection was unknown.  The causality assessment between papilloma viral infection and the suspect vaccine was not provided by the reporter.
This spontaneous report has been received from a nurse practitioner regarding a patient of unknown age and gender. The patient's concurrent condition, medical history and concomitant medications were not reported. On 05-APR-2013, the patient was vaccinated VARIVAX dose 1, lot # 0610AE (dose, vaccination site, expiry date unknown). No adverse effects were reported. The reporter stated that inconsistencies in storage temperature were identified on extensive review and records. The reporter stated that vaccine was not thawed. The nurse practitioner reported that there was insufficient data to provide 100 percent assurance on vaccine stability. This is one of the several reports received from the same reporter. Additional information has been requested.